MARKET NEWS

 

Entasis Therapeutics & Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial
AC Immune Acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) Anti-Alpha-Synuclein Programs Targeting Neurodegenerative Diseases
Dyadic Announces Technology Transfer & Licensing Agreement With South Africa’s Rubic Consortium
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity & Licenses GlymaxX
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
Catalent Launches New OptiDose Design Solution to Help Create Differentiated Treatments That Are Successful for Innovators, Patients & Health Care Professionals

  FEATURED EDITORIAL

  COMPANY PROFILE

Now employing over 900 people, the publicly listed (6472.TWO) Bora Pharmaceuticals is a premier, international, CGMP, CDMO specializing in complex oral solid dose (tablet, granules & capsules), liquids (solutions, suspensions, & nasal sprays) and semisolid (creams, lotions & gels) pharmaceutical Rx and OTC products for late-phase Clinical through Commercial manufacturing and packaging. Bora owns and operates three state-of-the-art CGMP manufacturing facilities in Taiwan and Canada that are built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity & Injectable Drug Product Services

Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity & Injectable Drug Product Services

Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced it has acquired Drug Delivery Experts, LLC (DDE)…..

CatSci & Argonaute RNA Partner to Expedite Oligonucleotide Manufacturing for Gene-Silencing Therapeutics

CatSci & Argonaute RNA Partner to Expedite Oligonucleotide Manufacturing for Gene-Silencing Therapeutics

CatSci Ltd and Argonaute RNA recently announced a chemistry, manufacturing, and control (CMC) development collaboration focused on novel therapeutic oligonucleotides…..

Lantern Pharma & Allarity Therapeutics Enter Into Agreement for Future Clinical Development of Irofulven

Lantern Pharma & Allarity Therapeutics Enter Into Agreement for Future Clinical Development of Irofulven

Allarity Therapeutics A/S and Lantern Pharma Inc. recently announced they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full….

Organon & ObsEva Enter Global Development & Commercialization License Agreement 

Organon & ObsEva Enter Global Development & Commercialization License Agreement 

Organon and ObsEva recently announced they have entered into an agreement whereby Organon will license the global development, manufacturing, and commercial rights to ebopiprant….

Abzena & BioXpress Therapeutics Announce Development & Manufacturing Partnership

Abzena & BioXpress Therapeutics Announce Development & Manufacturing Partnership

Abzena and BioXpress Therapeutics recently announced their partnership to support biosimilar development for third-party customers. The partnership creates an….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 11 – Analytical Testing
August 18 – ODT/Fast Dissolve